Conclusion:Pegmolesatide ameliorates CKD-associated mitochondrial dysfunction and cardiomyocyte hypertrophy by antagonizing CD131/ EPOR heterodimerization and suppressing the overactivation of the JAK2/STAT3 pathway (Fig. 7).This study demonstrates the pleiotropic effects of Pegmolesatide, providing a theoretical basis for its cardiorenal protective role in CKD patients.The content of this abstract was previously submitted to CCSN2025.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Koh et al. (Wed,) studied this question.